SCHEMBL21634014

SCHEMBL21634014

NCC(O)COc1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TSHR P16473 1/20 0.46
RAB9A P51151 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KCNH2 Q12809 1/20 0.45
MAOB P27338 2/20 0.44
GAA P10253 1/20 0.44
POLB P06746 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALOX15 P16050 1/20 0.43
NR2E1 Q9Y466 1/20 0.43
C5AR1 P21730 1/20 0.43
UBE2N P61088 1/20 0.43
ABCB1 P08183 3/20 0.43
ALOX5 P09917 1/20 0.43
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21634013 1.00 KMT2A (0.48) KMT2ASMN1; SMN2TSHRRAB9AHSD17B10
SCHEMBL25290710 0.86 MAOB (0.47) KMT2ASMN1; SMN2KCNH2MAOB
SCHEMBL25290709 0.86 MAOB (0.47) KMT2ASMN1; SMN2KCNH2MAOB
SCHEMBL10923979 0.85 KCNH2 (0.58) SMN1; SMN2TSHRKCNH2L3MBTL1ALOX15
SCHEMBL6075106 0.85 RAB9A (0.59) KMT2ASMN1; SMN2TSHRRAB9AHSD17B10
SCHEMBL6797677 0.85 RAB9A (0.59) KMT2ASMN1; SMN2TSHRRAB9AHSD17B10
SCHEMBL773087 0.84 MAOB (0.59) KMT2ASMN1; SMN2TSHRRAB9AHSD17B10
SCHEMBL21811960 0.84 ADRB2 (0.53) KMT2ASMN1; SMN2RAB9AABCB1
SCHEMBL21811961 0.84 ADRB2 (0.53) KMT2ASMN1; SMN2RAB9AABCB1
SCHEMBL10926521 0.84 KMT2A (0.53) KMT2ASMN1; SMN2TSHRRAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3828162-B1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES COMPRISING THE SAME AUTOTAC INC (KR) 2025-07-09 EP disclosed
US-11981618-B2 P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same AUTOTAC INC. (KR) 2024-05-14 US disclosed
CN-112672993-B Novel AUTOTAC chimeric compounds and compositions comprising same for preventing, ameliorating or treating diseases by targeted protein degradation 奧土择破利悟株式会社 2024-03-08 CN disclosed
US-20210347749-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME PROTECH CO., LTD. (KR) 2021-11-11 US disclosed
EP-3828162-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, ALLEVIATING, OR TREATING PROTEIN ABNORMALITY DISORDERS Protech Co., Ltd. (KR) 2021-06-02 EP disclosed
WO-2020022783-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, ALLEVIATING, OR TREATING PROTEIN ABNORMALITY DISORDERS 주식회사 프로텍바이오 2020-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210347749-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME SQSTM1, ATG7, BECN1 KMT2A 3635/4885SMN1; SMN2 327/4885TSHR 4433/4885
US-11981618-B2 P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same SQSTM1, ATG7, BECN1 KMT2A 3453/4885SMN1; SMN2 391/4885TSHR 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.